Skip to main content
. 2012 Aug 15;120(11):1607–1612. doi: 10.1289/ehp.1104242

Figure 1.

Figure 1

MSDs during the previous 2 weeks at baseline (blue) and 12 months (gray) for HEAL (all participants), ICAS, and NCICAS participants who received the study intervention. Changes in MSDs are shown with 95% CIs and p-values comparing symptoms at baseline and 12 months.